AEON Biopharma, Inc. 8-K

What Happened
AEON Biopharma, Inc. announced its financial results for the year ended December 31, 2025 in a press release dated March 30, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to disclose the results and furnished the press release as Exhibit 99.1. The filing was signed by Robert Bancroft, President and CEO.

Key Details

• Announcement date: March 30, 2026.
• Reporting period: year ended December 31, 2025.
• Press release with the financial results is furnished as Exhibit 99.1 to the Form 8-K.
• The Form 8-K also includes the Inline XBRL cover page (Exhibit 104). No other material items (e.g., executive changes, mergers) were reported in this filing.

Why It Matters
This filing notifies investors that AEON has publicly reported its full-year 2025 results; the press release will contain the specific earnings, revenue, and cash/operating metrics investors need to assess performance. Because the 8-K does not report management changes or other material transactions, the primary takeaway for shareholders is the released financial data—review the Exhibit 99.1 press release (and the company’s earnings materials) to evaluate revenue, profit/loss, cash position, and any guidance or commentary management provided.